Detalhe da pesquisa
1.
Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach.
Int J Mol Sci
; 22(15)2021 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34360800
2.
Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab.
J Clin Med
; 13(5)2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38592150
3.
Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for more than 1 Year.
Cancer Res Treat
; 2024 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38810969
4.
Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma.
Liver Cancer
; 13(1): 89-98, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38344445
5.
Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification.
J Clin Transl Hepatol
; 11(3): 747-750, 2023 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36969903
6.
High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma.
J Cancer
; 14(6): 935-942, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37151396
7.
The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.
Front Oncol
; 12: 811247, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35311091
8.
High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma.
Cancers (Basel)
; 14(23)2022 Dec 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36497467
9.
Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.
Ther Adv Med Oncol
; 13: 17588359211035983, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34394748